Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Matrixyl Synthe'6 (Palmitoyl Tripeptide-38)
Overview
Palmitoyl tripeptide-38 is a synthetic lipopeptide designed to stimulate synthesis of six major constituents of the dermal matrix: collagen I, III, and IV, fibronectin, hyaluronic acid, and laminin 5. It is proposed to activate transforming growth factor beta (TGF-beta) signaling in fibroblasts, thereby promoting coordinated extracellular matrix assembly.
Mechanism of Action
The palmitic acid conjugate enhances dermal bioavailability when applied topically.
Research Summary & Key Findings
In vitro studies using cultured human dermal fibroblasts have demonstrated dose-dependent increases in collagen I, III, and IV mRNA expression, along with elevated hyaluronic acid production. A small manufacturer-supported clinical trial reported volumetric improvements in nasolabial fold depth after 60 days of topical use, though peer-reviewed validation is lacking. Histological confirmation of matrix remodeling in human skin has not been extensively published.
Clinical Status
Matrixyl Synthe'6 (Palmitoyl Tripeptide-38) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Matrixyl Synthe'6"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Matrixyl Synthe'6"
Registered interventional and observational studies, including status and phase.
- PubChem: "Matrixyl Synthe'6"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Dermatology
Afamelanotide (Scenesse)
FDA ApprovedA synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine a...
View detailsArgireline (Acetyl Hexapeptide-8)
InvestigationalArgireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter...
View detailsMatrixyl (Palmitoyl Pentapeptide-4)
InvestigationalMatrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety t...
View detailsMatrixyl 3000
InvestigationalMatrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapept...
View detailsNo lawful pathway today
Matrixyl Synthe'6 (Palmitoyl Tripeptide-38) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.